Purdue Pharma Wins Approval for Abuse-Deterrent Pain Pill
This article is for subscribers only.
Purdue Pharma LP won approval for an extended-release pure hydrocodone painkiller, the first to hit the market deemed to deter abuse.
The Food and Drug Administration said today it cleared the drug Hysingla ER with a label that indicates the tablet is difficult to abuse via injection or snorting. Closely held Purdue’s Hysingla will compete with the only other approved pure hydrocodone medicine, Zogenix Inc.’s Zohydro. The drugs are intended to be liver-friendly alternatives to drugs including Vicodin that mix hydrocodone with less-potent medicines such as acetaminophen.